Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGEM NASDAQ:GALT NASDAQ:OLMA NASDAQ:PURR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGEMCullinan Therapeutics$18.13$15.61$5.68▼$19.43$1.11B-0.011.16 million shs684,715 shsGALTGalectin Therapeutics$4.06$2.98$2.03▼$7.13$267.39M0.351.12 million shs528,579 shsOLMAOlema Pharmaceuticals$11.91$12.17$4.37▼$36.26$1.04B21.85 million shs927,028 shsPURRHyperliquid Strategies$7.55$8.21$3.01▼$11.62$1.09B1.6613.17 million shs8.87 million shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGEMCullinan Therapeutics0.00%+2.84%+32.34%+27.23%+135.45%GALTGalectin Therapeutics0.00%-9.98%+52.06%+72.77%+61.75%OLMAOlema Pharmaceuticals0.00%-5.78%+20.67%-25.24%+156.13%PURRHyperliquid Strategies0.00%-6.21%-13.22%+16.15%+754,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGEMCullinan Therapeutics$18.13$15.61$5.68▼$19.43$1.11B-0.011.16 million shs684,715 shsGALTGalectin Therapeutics$4.06$2.98$2.03▼$7.13$267.39M0.351.12 million shs528,579 shsOLMAOlema Pharmaceuticals$11.91$12.17$4.37▼$36.26$1.04B21.85 million shs927,028 shsPURRHyperliquid Strategies$7.55$8.21$3.01▼$11.62$1.09B1.6613.17 million shs8.87 million shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGEMCullinan Therapeutics0.00%+2.84%+32.34%+27.23%+135.45%GALTGalectin Therapeutics0.00%-9.98%+52.06%+72.77%+61.75%OLMAOlema Pharmaceuticals0.00%-5.78%+20.67%-25.24%+156.13%PURRHyperliquid Strategies0.00%-6.21%-13.22%+16.15%+754,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGEMCullinan Therapeutics 2.63Moderate Buy$32.0076.50% UpsideGALTGalectin Therapeutics 2.00Hold$11.00170.94% UpsideOLMAOlema Pharmaceuticals 2.71Moderate Buy$44.10270.28% UpsidePURRHyperliquid Strategies 2.50Moderate Buy$12.7268.43% UpsideCurrent Analyst Ratings BreakdownLatest GALT, PURR, CGEM, and OLMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/8/2026CGEMCullinan Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/1/2026PURRHyperliquid Strategies Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$8.00 ➝ $18.406/23/2026GALTGalectin Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.006/18/2026GALTGalectin Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/12/2026PURRHyperliquid Strategies Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.756/11/2026CGEMCullinan Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$37.006/8/2026CGEMCullinan Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.006/3/2026PURRHyperliquid Strategies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)5/22/2026OLMAOlema Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/20/2026PURRHyperliquid Strategies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (D)5/20/2026PURRHyperliquid Strategies Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.45 ➝ $9.75(Data available from 7/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGEMCullinan TherapeuticsN/AN/AN/AN/A$6.92 per shareN/AGALTGalectin TherapeuticsN/AN/AN/AN/A($1.99) per shareN/AOLMAOlema PharmaceuticalsN/AN/AN/AN/A$5.88 per shareN/APURRHyperliquid Strategies$1M1,090.60N/AN/A$1.52 per share4.97Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGEMCullinan Therapeutics-$219.88M-$3.36N/AN/AN/AN/A-51.45%-47.64%8/6/2026 (Estimated)GALTGalectin Therapeutics-$30.84M-$0.41N/AN/AN/AN/AN/A-164.69%8/13/2026 (Estimated)OLMAOlema Pharmaceuticals-$162.45M-$2.02N/AN/AN/AN/A-46.00%-41.22%8/10/2026 (Estimated)PURRHyperliquid Strategies-$16.01M-$7.37N/AN/AN/AN/A-56.04%-52.22%N/ALatest GALT, PURR, CGEM, and OLMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/10/2026Q2 2026OLMAOlema Pharmaceuticals-$0.53N/AN/AN/AN/AN/A8/6/2026Q2 2026CGEMCullinan Therapeutics-$0.7994N/AN/AN/A$3.67 millionN/A5/15/2026Q1 2026GALTGalectin Therapeutics-$0.06-$0.08-$0.02-$0.08N/AN/A5/12/2026Q1 2026OLMAOlema Pharmaceuticals-$0.52-$0.52N/A-$0.52N/AN/A5/7/2026Q1 2026CGEMCullinan Therapeutics-$0.8359-$0.75+$0.0859-$0.75$3.67 millionN/A5/7/2026Q3 2026PURRHyperliquid StrategiesN/A$1.01N/A$1.01N/A$2.63 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCGEMCullinan TherapeuticsN/AN/AN/AN/AN/AGALTGalectin TherapeuticsN/AN/AN/AN/AN/AOLMAOlema PharmaceuticalsN/AN/AN/AN/AN/APURRHyperliquid StrategiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGEMCullinan TherapeuticsN/A10.2810.28GALTGalectin TherapeuticsN/A2.152.15OLMAOlema Pharmaceuticals0.0110.8810.88PURRHyperliquid StrategiesN/A18.2318.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGEMCullinan Therapeutics86.31%GALTGalectin Therapeutics11.68%OLMAOlema Pharmaceuticals91.78%PURRHyperliquid Strategies9.45%Insider OwnershipCompanyInsider OwnershipCGEMCullinan Therapeutics8.60%GALTGalectin Therapeutics52.60%OLMAOlema Pharmaceuticals12.56%PURRHyperliquid Strategies8.48%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGEMCullinan Therapeutics3061.46 million56.17 millionOptionableGALTGalectin Therapeutics965.86 million31.22 millionOptionableOLMAOlema Pharmaceuticals7087.35 million76.38 millionOptionablePURRHyperliquid StrategiesN/A144.45 million132.20 millionN/AGALT, PURR, CGEM, and OLMA HeadlinesRecent News About These CompaniesHyperliquid Strategies (NASDAQ:PURR) Shares Gap Up - Time to Buy?July 10 at 10:59 AM | marketbeat.comDefiance Launches PUR: The First 2X Long PURR ETFJuly 8, 2026 | globenewswire.comTraders Purchase Large Volume of Hyperliquid Strategies Call Options (NASDAQ:PURR)July 8, 2026 | americanbankingnews.comWhy Money Is Leaving Bitcoin for HyperliquidJuly 3, 2026 | aol.comAHyperliquid Strategies Inc (NASDAQ:PURR) Sees Significant Growth in Short InterestJuly 2, 2026 | americanbankingnews.comHyperliquid Strategies Inc Added to the Russell 3000, Russell 2000 and S&P Global BMI IndicesJune 29, 2026 | prnewswire.comHyperliquid Strategies Enhances Executive Compensation and Leadership StructureJune 26, 2026 | tipranks.comPanther Minerals Announces Brokered Private Placement of up to $3,000,000June 16, 2026 | accessnewswire.comAHyperliquid Strategies shares jump as HYPE token strength and late-June index reconstitution fuel buyingJune 16, 2026 | quiverquant.comQHyperliquid Strategies Stock Is Surging Tuesday: What's Driving The Action?June 16, 2026 | benzinga.comWhy Is Hyperliquid Strategies Stock Gaining Monday?June 15, 2026 | benzinga.comPanther Minerals Announces Appointment of Harrison Glancy to Board of DirectorsJune 10, 2026 | accessnewswire.comAHyperliquid Strategies (PURR) Is Down 14.6% After Gamma Squeeze Speculation and Index Inclusion Buzz – What's ChangedJune 7, 2026 | finance.yahoo.comComparing HYPE & PURR: The Most Stock-Like Crypto PlayJune 5, 2026 | seekingalpha.comArthur Hayes: My $100,000 Against Yours That SOL Will Not Outperform The Hottest Coin In The MarketJune 2, 2026 | benzinga.comPURR Stock On Track For Record High After Hyperliquid Flips Dogecoin To Enter Crypto Top 10June 1, 2026 | finance.yahoo.comHyperliquid Is 'Bigger Than Nasdaq,' Says ICE CEO — HYPE Eyes New Record High, While ETFs Top $100MMay 30, 2026 | finance.yahoo.comHyperliquid Strategies (PURR) jumps as Russell Microcap inclusion chatter lifts demandMay 29, 2026 | quiverquant.comQWhy Hyperliquid Strategies Inc.’s (PURR) Stock Is Up 12.26%May 28, 2026 | aaii.comAGoldman Sachs Sells XRP and SOL ETF, Pivots to Hyperliquid in Q1 2026May 22, 2026 | memeburn.comMHyperliquid token surges toward all-time high after spot ETF inflows hit record – 'Everything is down lately except HYPE,' says analystMay 22, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGALT, PURR, CGEM, and OLMA Company DescriptionsCullinan Therapeutics NASDAQ:CGEM$18.13 0.00 (0.00%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$18.06 -0.07 (-0.41%) As of 08:32 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Galectin Therapeutics NASDAQ:GALT$4.06 0.00 (0.00%) As of 07/10/2026 04:00 PM EasternGalectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.Olema Pharmaceuticals NASDAQ:OLMA$11.91 0.00 (0.00%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$11.86 -0.05 (-0.42%) As of 07:18 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.Hyperliquid Strategies NASDAQ:PURR$7.55 0.00 (0.00%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$7.32 -0.23 (-3.05%) As of 08:36 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Hyperliquid Strategies Inc is a digital asset treasury company whose primary focus is to maximize shareholder value through accumulating HYPE, the native token of Hyperliquid, a high-performance blockchain custom-built to house all of finance. Hyperliquid Strategies Inc, formerly known as Sonnet BioTherapeutics Holdings Inc., is based in NEW YORK. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/06 - 07/10 Delta Air Lines Lives Up to Its Claims: Shares Can Keep Climbing Why WD-40 Is Proving Great Businesses Never Go Out of Style Rocket Lab’s Stock Drop Comes With a Bullish Twist Why "Big Short" Investor Michael Burry Sees Upside in Beaten-Down Sportbook Stocks Microsoft Bets on In-House AI to Cut OpenAI and Anthropic Costs Power Struggle: Wolfspeed Sues Navitas Over AI Chips Pushing the Edge: Super Micro Computer Reboots the AI Landscape Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
